Journal: CNS Neuroscience & Therapeutics
Article Title: Myricetin Suppresses Inflammatory Th17 Polarization to Mitigate Alzheimer's Disease Pathogenesis
doi: 10.1111/cns.70644
Figure Lengend Snippet: Improving effects of myricetin on AD pathology. (A) Thioflavin T staining in the hippocampus ( n = 5). Bars, 1000 μm for low magnification and 100 μm for high magnification. (B) Number of Aβ‐positive plaques. (C) Representative Western blot bands of APP, P‐Tau, and GAPDH ( n = 5). (D) Relative expression levels of APP and P‐Tau proteins. (E) Fluorescence images of APP and P‐Tau ( n = 5). Bars, 40 μm. (F, G) Analysis of APP and P‐Tau fluorescence intensity. (H, I) Immunohistochemical images and analysis of Aβ in mice ( n = 5). Bars, 1000 μm for low magnification and 50 μm for high magnification. (J) ELISA of Aβ concentration in serum ( n = 5). ## p < 0.01, ### p < 0.001 compared to the WT group; ** p < 0.01, *** p < 0.001 compared to the AD group.
Article Snippet: After protein transfer, the membranes were blocked for 1 h, washed, and incubated with primary antibodies: APP (255241‐AP, Proteintech), P‐Tau (28666‐1‐AP, Proteintech), GAPDH (AF2819, Beyotime) overnight at 4°C.
Techniques: Staining, Western Blot, Expressing, Fluorescence, Immunohistochemical staining, Enzyme-linked Immunosorbent Assay, Concentration Assay